{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:13:57Z","timestamp":1791422037041,"version":"4.3.3"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Gepotidacin is a novel triazaacenaphthylene topoisomerase inhibitor that has demonstrated non-inferiority to 500\u2005mg of intramuscular ceftriaxone plus 1\u2005g of oral azithromycin for the treatment of uncomplicated urogenital gonorrhoea. We evaluated gepotidacin in vitro activity against a panel of ceftriaxone-resistant Neisseria gonorrhoeae isolates that were referred to the UK Health Security Agency between 2015 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Gepotidacin and comparator antimicrobials were tested against 23 ceftriaxone-resistant (MIC \u22650.25\u2005mg\/L) N. gonorrhoeae isolates by agar dilution. Genomic sequences were examined for known resistance determinants and sequence types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Gepotidacin inhibited the majority (96%) of isolates at \u22642\u2005mg\/L, with MIC range, MIC50 and MIC90 values of 0.25\u20134, 0.5 and 2\u2005mg\/L, respectively. All 23 isolates had amino-acid modifications associated with ciprofloxacin resistance, including the rare GyrA A92P alteration in 10 isolates, none of which are believed to effect gepotidacin binding. All isolates had mutations causing the overexpression of the MtrCDE efflux pump and 10 isolates had mutations causing the overexpression of the NorM efflux pump. Nine different MLSTs were subdivided into 16 and 14 NG-MAST and NG-STAR types, respectively. MLST ST8123 was the most prevalent MLST and the gepotidacin MIC range against this sequence type was similar to the overall distribution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, gepotidacin was active in vitro against this challenging panel of ceftriaxone-resistant gonococcal clinical isolates. Gepotidacin activity does not seem to be affected in this ceftriaxone-resistant set of strains. A structural analysis suggests that the rare GyrA A92P alteration identified in this study does not affect gepotidacin binding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag001","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:27:38Z","timestamp":1767702458000},"source":"Crossref","is-referenced-by-count":4,"title":["<i>In vitro<\/i>\n                    activity of gepotidacin against a challenging panel of multidrug-resistant\n                    <i>Neisseria gonorrhoeae<\/i>\n                    isolates"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6707-6910","authenticated-orcid":false,"given":"Michelle Jayne","family":"Cole","sequence":"first","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Doumith","sequence":"additional","affiliation":[{"name":"Public Health Microbiology , UK Health Security Agency, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vickers","sequence":"additional","affiliation":[{"name":"Public Health Microbiology , UK Health Security Agency, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9086-9222","authenticated-orcid":false,"given":"Sarah","family":"Alexander","sequence":"additional","affiliation":[{"name":"Public Health Microbiology , UK Health Security Agency, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-403X","authenticated-orcid":false,"given":"Helen","family":"FIFER","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Day","sequence":"additional","affiliation":[{"name":"Public Health Microbiology , UK Health Security Agency, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Jakielaszek","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, GSK , Collegeville, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Scangarella-Oman","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, GSK , Collegeville, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Pitt-Kendall","sequence":"additional","affiliation":[{"name":"Public Health Microbiology , UK Health Security Agency, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"2026012305210026500_dkag001-B1","author":"Migchelsen"},{"key":"2026012305210026500_dkag001-B2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S1473-3099(21)00625-3","article-title":"Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial","volume":"22","author":"de Vries","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026012305210026500_dkag001-B3","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1093\/jac\/dkae369","article-title":"Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015-24: an observational analysis","volume":"79","author":"Fifer","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026012305210026500_dkag001-B4","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"2026012305210026500_dkag001-B5","doi-asserted-by":"publisher","first-page":"S642","DOI":"10.1093\/ofid\/ofaa439.1433","article-title":"1249: genetic evidence that gepotidacin shows well-balanced dual targeting against DNA gyrase and topoisomerase IV in Neisseria gonorrhoeae","volume":"7","author":"Chan","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026012305210026500_dkag001-B6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus Gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect Dis"},{"key":"2026012305210026500_dkag001-B7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1021\/acsinfecdis.3c00346","article-title":"Interactions between gepotidacin and Escherichia coli gyrase and topoisomerase IV: genetic and biochemical evidence for well-balanced dual-targeting","volume":"10","author":"Oviatt","year":"2024","journal-title":"ACS Infect Dis"},{"key":"2026012305210026500_dkag001-B8","doi-asserted-by":"publisher","first-page":"e00207-19","DOI":"10.1128\/AAC.00207-19","article-title":"Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations","volume":"63","author":"Szili","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012305210026500_dkag001-B9","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"2026012305210026500_dkag001-B10","volume-title":"ECCMID 2019. Amsterdam, Netherlands","author":"Mushtaq","year":"2019"},{"key":"2026012305210026500_dkag001-B11","doi-asserted-by":"publisher","first-page":"e01221-18","DOI":"10.1128\/AAC.01221-18","article-title":"Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae","volume":"62","author":"Scangarella-Oman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012305210026500_dkag001-B12","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/jac\/dky162","article-title":"In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae","volume":"73","author":"Jacobsson","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026012305210026500_dkag001-B13","volume-title":"The 2024 STI prevention conference. Atlanta, USA","author":"Jakielaszek","year":"2024"},{"key":"2026012305210026500_dkag001-B14","article-title":"Antimicrobial activity of gepotidacin against Neisseria gonorrhoeae isolates collected between 2018-2021","author":"Kapoor"},{"key":"2026012305210026500_dkag001-B15","author":"CLSI"},{"key":"2026012305210026500_dkag001-B16","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/jac\/dkae176","article-title":"The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains-phenotypic, genetic and reference genome characterization","volume":"79","author":"Unemo","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026012305210026500_dkag001-B17","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2026012305210026500_dkag001-B18","author":"Sun"},{"key":"2026012305210026500_dkag001-B19","author":"UK Health Security Agency"},{"key":"2026012305210026500_dkag001-B20","author":"CLSI"},{"key":"2026012305210026500_dkag001-B21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/09564624251339054","article-title":"BASHH annual conference 2025, Edinburgh, UK, June 9\u201311 2025: MP011\u2014multidrug-resistance in Neisseria gonorrhoeae: a new definition and trends 2016-2022","volume":"36","author":"Callan","year":"2025","journal-title":"Int J STD AIDS"},{"key":"2026012305210026500_dkag001-B22","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1128\/JB.185.3.1101-1106.2003","article-title":"The NorM efflux pump of Neisseria gonorrhoeae and Neisseria meningitidis recognizes antimicrobial cationic compounds","volume":"185","author":"Rouquette-Loughlin","year":"2003","journal-title":"J Bacteriol"},{"key":"2026012305210026500_dkag001-B23","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/jac\/dkae217","article-title":"In silico gepotidacin target mining among 33213 global Neisseria gonorrhoeae genomes from 1928 to 2023 combined with gepotidacin MIC testing of 22 gonococcal isolates with different GyrA and ParC substitutions","volume":"79","author":"David","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026012305210026500_dkag001-B24","doi-asserted-by":"publisher","first-page":"e02047-16","DOI":"10.1128\/AAC.02047-16","article-title":"In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae","volume":"61","author":"Farrell","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkag001\/66555519\/dkag001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkag001\/66555519\/dkag001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:21:10Z","timestamp":1769163670000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag001\/8439340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag001","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkag001"}}